ResMed Inc Stock (ISIN: AU000000RMD6) Faces Pressure Amid Recent Declines: What European Investors Need to Know

ResMed Inc stock (ISIN: AU000000RMD6), a global leader in sleep and respiratory care devices, has come under selling pressure in early March 2026, with shares on the ASX dropping from above $36 to around $32.63 as of March 17. This pullback follows solid Q2 results in late January, where the company beat earnings expectations, yet broader market dynamics and profit-taking appear to weigh on sentiment. For English-speaking investors in Europe, particularly in the DACH region, ResMed's defensive healthcare profile and low debt make it a compelling hold amid volatility.

As of: 19.03.2026

By Dr. Elena Voss, Senior Healthcare Equity Analyst - Specializing in MedTech innovation and European cross-listing opportunities for DACH portfolios.

Current Market Snapshot for ResMed Inc Stock

ResMed shares on the NYSE opened at $233.60 recently, reflecting a dip from 50-day and 200-day moving averages of approximately $254 and $257, respectively, with a 52-week range of $199.92 to $293.81. On the ASX, under ticker RMD, the stock closed at $32.63 on March 17, down 0.61% that day after a steeper 3.13% drop on March 12, amid trading volumes spiking to over 1.4 million shares on several sessions. Market capitalization stands around $33-34 billion USD, positioning ResMed as the 713th most valuable company globally.

This dual-listing structure - NYSE:RMD primary and ASX:RMD - allows European investors access via Xetra or Deutsche Boerse, where liquidity supports DACH portfolios seeking US healthcare exposure without direct NYSE trading costs. The stock's beta of 0.88 signals lower volatility, attractive for risk-averse Swiss or German funds.

Strong Q2 Earnings Drive Fundamentals

ResMed reported Q2 earnings per share of $2.81, surpassing consensus estimates of $2.68, with revenue at $1.42 billion, up 11% year-over-year and beating $1.40 billion forecasts. Net margins hit 27.53% and return on equity 25.20%, underscoring operational leverage in its core sleep apnea mask and device segment. The beat highlights resilient demand for connected health solutions, even as macroeconomic pressures linger.

For DACH investors, this performance aligns with Europe's aging population trends, where sleep-disordered breathing affects over 30 million adults in the EU. ResMed's cloud-connectivity platform, myAir, boosts patient adherence and recurring SaaS revenue, differentiating it from pure hardware players.

Analyst Sentiment Remains Positive

Consensus rating for ResMed is 'Moderate Buy', with one Strong Buy, nine Buy, and four Hold ratings; average target $299.27 implies upside from current levels. Recent upgrades include Citigroup to $345 'buy' on February 2, Royal Bank of Canada to $314 'outperform' on January 30, and Piper Sandler to $275 'neutral'. Expected fiscal year EPS of 9.47 supports growth outlook.

European analysts echo this, viewing ResMed's low debt-to-equity of 0.06 and current ratio of 3.06 as buffers against rate hikes impacting eurozone peers. Quarterly dividend of $0.60 ($2.40 annual, ~1% yield) appeals to income-focused Austrian funds.

Business Model: Installed Base and Recurring Revenue

ResMed operates as a medtech pure-play focused on sleep-disordered breathing and chronic respiratory conditions, with products like CPAP machines, masks, and cloud software. The 'razor-razorblade' model drives consumables pull-through from a growing installed base, enhanced by digital therapeutics. Revenue mix favors high-margin SaaS and accessories over devices.

In Europe, ResMed benefits from regulatory tailwinds like EU MDR compliance and rising OSA diagnosis rates in Germany, where 12 million adults are affected. DACH investors value this stability versus cyclical industrials, with 54.98% institutional ownership signaling conviction.

Institutional Flows and Insider Activity

Recent institutional moves include Captrust Financial Advisors buying 27,565 shares and Arizona State Retirement System selling 3,297, net positive for ownership. Insider sales, like a director offloading 2,000 shares at $260.22 and CEO 4,991 at $248.46 in January, reflect profit-taking post-earnings, not distress given post-sale holdings.

For Swiss investors, these flows indicate smart money accumulation at dips, aligning with low-beta defensiveness. Hedge funds hold significant stakes, supporting liquidity on Xetra.

European and DACH Investor Perspective

ResMed's ASX listing (AU000000RMD6) enables easy access for German and Austrian retail via Gettex or regional brokers, while Swiss portfolios track it for healthcare diversification. Euro-denominated exposure mitigates USD swings, crucial amid ECB policy divergence from Fed easing. Sector relevance grows with Europe's telemedicine push post-COVID.

DACH funds, managing over €2 trillion in healthcare assets, favor ResMed's 27% margins and cash generation over volatile biotech. Potential for dividend growth and buybacks enhances total return appeal.

Segment Drivers and End-Market Demand

Sleep apnea device revenue leads, bolstered by obesity epidemic and awareness campaigns. Cloud-connectivity, via AirSense 11 and myAir app, lifts adherence to 70%+ , driving SaaS ARR growth. Respiratory care benefits from post-acute demand.

Challenges include supply chain normalization and competition from Philips (recall-hit), but ResMed's market share gains persist. European growth hinges on reimbursement expansions in Germany and France.

Margins, Cash Flow, and Capital Allocation

Gross margins benefit from mix shift to software (50%+ margins) and scale. Operating leverage evident in Q2, with free cash flow supporting $0.60 dividend hikes and $1B+ buybacks historically. Balance sheet strength (quick ratio 2.32) funds M&A in digital health.

DACH investors prioritize this discipline, contrasting high-capex medtech peers. PEG ratio of 1.53 suggests fair valuation at 23x PE.

Competition, Risks, and Catalysts

Competitors like Fisher & Paykel andDrive DeVilbiss lag in digital integration, but Philips recovery poses risks. Macro headwinds include healthcare spending cuts in Europe. Catalysts: Q3 earnings (late April), new product launches, potential tuck-in acquisitions.

Risks encompass reimbursement changes in DACH markets and forex volatility (AUD/USD exposure). Upside from OSA prevalence rising 2-3% annually.

Technical Setup and Outlook

ASX shares test support near $32, with RSI oversold; rebound to $35+ possible on volume. NYSE 50-day MA at $254 offers resistance. Moderate Buy consensus targets 20-40% upside.

For long-term DACH holders, ResMed's moat in connected sleep care positions it for 10%+ CAGR, making dips buyable. Monitor institutional flows and upcoming guidance for conviction.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.